XMADECR
Market cap337mUSD
Dec 20, Last price
3.54EUR
1D
-0.28%
1Q
-4.32%
Jan 2017
92.39%
Name
Ercros SA
Chart & Performance
Profile
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing chipboards, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; plugs and switches in the electrical components sector; and household, sanitary, and packaging materials in the textile tanning industry. The Pharmacy division engages in the production of raw materials and intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, calcium and sodium fosfomycin, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.
IPO date
Sep 17, 1990
Employees
1,343
Domiciled in
ES
Incorporated in
ES
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 725,294 -27.36% | 998,532 24.81% | 800,055 40.66% | |||||||
Cost of revenue | 529,712 | 756,913 | 587,004 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 195,582 | 241,619 | 213,051 | |||||||
NOPBT Margin | 26.97% | 24.20% | 26.63% | |||||||
Operating Taxes | (23,764) | 17,314 | 7,859 | |||||||
Tax Rate | 7.17% | 3.69% | ||||||||
NOPAT | 219,346 | 224,305 | 205,192 | |||||||
Net income | 27,585 -56.21% | 62,989 45.48% | 43,297 591.98% | |||||||
Dividends | (13,715) | (8,211) | ||||||||
Dividend yield | 5.55% | 2.69% | ||||||||
Proceeds from repurchase of equity | (11,134) | (14,380) | (6,522) | |||||||
BB yield | 4.51% | 4.71% | 2.22% | |||||||
Debt | ||||||||||
Debt current | 31,732 | 30,945 | 24,601 | |||||||
Long-term debt | 108,777 | 116,806 | 101,627 | |||||||
Deferred revenue | 13,334 | 12,802 | 10,997 | |||||||
Other long-term liabilities | 19,686 | 23,080 | 12,893 | |||||||
Net debt | 42,845 | 53,515 | 82,343 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 51,140 | 62,989 | 60,324 | |||||||
CAPEX | (14,194) | (27,184) | (12,901) | |||||||
Cash from investing activities | (33,835) | (52,814) | (34,238) | |||||||
Cash from financing activities | (35,911) | (21,455) | (14,679) | |||||||
FCF | 229,759 | 191,883 | 174,042 | |||||||
Balance | ||||||||||
Cash | 39,145 | 55,480 | 50,305 | |||||||
Long term investments | 58,519 | 38,756 | (6,420) | |||||||
Excess cash | 61,399 | 44,309 | 3,882 | |||||||
Stockholders' equity | 363,115 | 431,335 | 381,432 | |||||||
Invested Capital | 465,985 | 483,364 | 467,254 | |||||||
ROIC | 46.21% | 47.19% | 47.82% | |||||||
ROCE | 35.49% | 43.88% | 42.79% | |||||||
EV | ||||||||||
Common stock shares outstanding | 93,587 | 94,229 | 98,781 | |||||||
Price | 2.64 -18.52% | 3.24 9.09% | 2.97 38.14% | |||||||
Market cap | 247,070 -19.07% | 305,303 4.06% | 293,380 32.98% | |||||||
EV | 289,915 | 358,818 | 375,723 | |||||||
EBITDA | 195,582 | 271,585 | 247,601 | |||||||
EV/EBITDA | 1.48 | 1.32 | 1.52 | |||||||
Interest | 9,793 | 3,787 | 3,794 | |||||||
Interest/NOPBT | 5.01% | 1.57% | 1.78% |